AI Defense Stock VisionWave Holdings (Nasdaq: $VWAV) Announces $20 Million Order for 200 Unmanned Ground Vehicles; @VWAVInc

 

AI Defense Stock VisionWave Holdings (Nasdaq: $VWAV) Announces $20 Million Order for 200 Unmanned Ground Vehicles; @VWAVInc

 

 

 

Investorideas.com, a top rated investment site for retail Investors following AI and defense stocks, reports on breaking news and trading for VisionWave Holdings, Inc (Nasdaq:VWAV), a technology company focused on advanced defense and autonomous systems.

 

VisionWave Holdings today announced that it has countersigned and accepted a purchase order from Metal Machinery Components Trading FZCO, a trading company registered in Dubai, United Arab Emirates (the “Customer”), for 200 STRATUM VARAN heavy wheeled unmanned ground vehicles at an aggregate base purchase price of $20 million. The Customer is not the end user of the vehicles and has advised the Company that it may act in relation to more than one prospective end user, each of which must be disclosed to and approved by VisionWave. VisionWave’s obligations to commence production, incur procurement commitments or make any delivery are subject to conditions that have not been satisfied, as described below.

 

Paid News Dissemination on behalf of VWAV 

 

Read this news, featuring VWAV in full at https://www.investorideas.com/CO/VWAV/news/2026/09241-ai-defense-stock-visionwave-holdings-nasdaq-vwav-announces-20-million-order-for-200-unmanned-ground-vehicles.asp

 

Editorial relevance to defense sector:

VisionWave’s STRATUM VARAN order is relevant because a multi-batch commercial purchase of this size is a rare external signal that buyers see a modular, AI-enabled UGV as operationally useful rather than experimental. If the conditions close, 200 vehicles is enough to matter at unit level: training pipelines, tactics, sustainment, and sensor-to-shooter software all get a real fleet instead of a handful of prototypes. That is why the announcement lands in the same conversation as broader defense modernization—autonomy, electronic sensing, and attritable ground mass—while investors and operators should still treat it as a conditional milestone, not booked revenue.

 

If and when certain conditions are satisfied or waived, deliveries are contemplated in three batches — 70 vehicles within 12 months, 70 vehicles in months 13 through 24 and 60 vehicles in months 25 through 36 — in each case measured from the date on which the last condition is satisfied or waived, and not from the date of the purchase order or of this release.

 

The purchase order provides for an advance payment of $2 million, representing 10% of the order value, to be secured by an advance-payment bank guarantee, with the balance payable against production, inspection and acceptance, and delivery milestones for each batch. The terms of the bank guarantee have not been agreed, and VisionWave has not received the advance payment or any other amount under the purchase order.

 

VisionWave’s performance under the purchase order is subject to the satisfaction, or written waiver by VisionWave, of a number of conditions, including delivery by the Customer of documentary proof of immediately available funds or committed financing sufficient to cover the full order value; agreement on the form, issuing bank, expiry and draw conditions of an advance-payment bank guarantee and receipt of the advance payment in cleared funds; receipt of all export licences, authorisations, end-user documentation and governmental approvals required in the United States, the country of manufacture, the United Arab Emirates and each jurisdiction of end use; and completion, to VisionWave’s satisfaction, of sanctions, anti-money-laundering, anti-bribery, export-control, beneficial-ownership and end-user compliance review. No production, procurement or delivery obligation arises, and no delivery milestone begins to run, until the last of those conditions is satisfied or waived. As of the date of this release, none of those conditions has been satisfied, and VisionWave can give no assurance as to whether or when any of them will be satisfied.

 

“An order of this size is an important commercial validation for the STRATUM VARAN platform,” said Douglas Davis, Chief Executive Officer of VisionWave. “We are working with the customer to satisfy the funding, security and regulatory conditions that must be met before production can begin, and we intend to report on that progress as it develops.”

 

VisionWave has not recognized any revenue in respect of the purchase order and does not include the order in backlog. Revenue, if any, will be recognized only as the applicable performance obligations are satisfied. Investors should not regard the aggregate order value as a firm order or as an indication of expected revenue in any period. Additional information regarding the purchase order is contained in VisionWave’s Current Report on Form 8-K filed with the Securities and Exchange Commission on September 24, 2026, which should be read together with this release.

 

About STRATUM VARAN

STRATUM VARAN is VisionWave’s heavy wheeled unmanned ground vehicle platform, which VisionWave is developing to support a range of operational applications and to accommodate multiple configurations and mission requirements. The platform has not completed the demonstration, qualification or acceptance testing contemplated by the purchase order, and its final configuration and technical characteristics will be established only in the technical annex to be agreed following that demonstration.

 

 

 

 

STRATUM VARAN — unmanned ground vehicle platform. A modular platform being developed for a range of autonomous and remote operations.

 

About VisionWave Holdings, Inc.

VisionWave Holdings, Inc. (Nasdaq: VWAV) is a defense and advanced sensing technology company developing AI-driven, RF-based sensing, autonomy, and computational acceleration technologies for defense, homeland security, and commercial infrastructure applications. VisionWave’s mission is to connect defense innovation with civilian progress through shared core technologies deployed across air, land, and fixed-site environments. The Company’s website is https://www.vwav.inc. Information contained on, or accessible through, the Company’s website is not incorporated by reference into, and does not form a part of, this press release or any filing of the Company with the Securities and Exchange Commission.

 

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “anticipate,” “believe,” “contemplate,” “expect,” “intend,” “may,” “plan,” “potential,” “project,” “schedule,” “should,” “will” and similar expressions, and include, without limitation, statements regarding the purchase order, the anticipated advance payment, the satisfaction of conditions, production, governmental, regulatory and export approvals, end-user approvals, manufacturing, delivery schedules, the demonstration and qualification of the STRATUM VARAN platform, the commercialization of that platform and VisionWave’s future business activities. 

 

Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including, among others: the Customer’s ability and willingness to deliver documentary proof of immediately available funds or committed financing for the full order value; the parties’ ability to agree the form and terms of, and to cause an acceptable bank to issue, the advance-payment bank guarantee, and the Customer’s ability to pay each milestone when due; VisionWave’s ability to obtain the export licenses, authorizations, end-user certificates and governmental approvals required in the United States, the country of manufacture, the United Arab Emirates and each jurisdiction of end use; the results of VisionWave’s sanctions, anti-money-laundering, anti-bribery, export-control, beneficial-ownership and end-user compliance review, including in respect of prospective end users in jurisdictions affected by ongoing armed conflict; the identification and approval of acceptable end users and the risk that end users are not approved or that approval is withdrawn; the results of the platform demonstration and the risk that requirements identified in that demonstration materially alter the base configuration, cost, schedule or qualification requirements; VisionWave’s ability to establish, finance and qualify manufacturing capacity, including any required local manufacturing or industrial participation, and to procure long-lead components on acceptable terms; increases in component, raw material, logistics and tariff costs; VisionWave’s dependence on a single customer and on intermediaries for this order; and VisionWave’s limited operating history, limited revenue to date, recurring losses, need for additional capital and the dilution associated with its existing and future financing arrangements.

 

There can be no assurance that the conditions under the purchase order will be satisfied on any anticipated timetable or at all, that the advance payment will be received, that required governmental, regulatory, export or end-user approvals will be obtained, that production will commence, or that all or any portion of the purchase order will result in completed deliveries, recognized revenue or earnings.

 

Additional information regarding risks and uncertainties affecting VisionWave is contained under “Risk Factors” in VisionWave’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025 and in its subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K filed with the Securities and Exchange Commission, which are available at www.sec.gov. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date made. VisionWave undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

 

Contact for Investors: investors@vwav.inc

 

VisionWave Holdings is a Featured Defense stock on Investorideaas.om

https://www.investorideas.com/CO/VWAV/

 

Research more defense stocks at Investorideas stock directory

https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp

 

Disclaimer/Disclosure: VisionWave Holdings, Inc. is a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info:  Learn more about publishing your news release and our other news services on the Investorideas.com newswire. Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:  https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com - Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Advertising agencies -Learn more about digital advertising and guest posts services  at Investorideas

https://www.investorideas.com/Advertise/

 

Follow & Contact

Follow us on X: @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube @Investorideas

 

This article was originally posted on Investorideas.com

 

 

Medical Tech Stock Aethlon Medical, Inc. (Nasdaq: $AEMD) Soars on Merger News

 

 

Medical Tech Stock Aethlon Medical, Inc. (Nasdaq: $AEMD) Soars on Merger News

 

 

 

(Investorideas.com Newswire) Investorideas.com, a trusted investment platform for retail investors reports breaking Medical Tech Stock news for  Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections for which there is no treatment.

 

The stock makes the Nasdaq top percentage gainers list today following merger news. The stock is trading at 7.05 +5.62 (+393.01%) on volume of over 78 Million shares as of this report. The stock has a morning high of $9.50.

 

Aethlon Medical, Inc. (Nasdaq: AEMD),today announced it  has entered into a definitive merger agreement (the "Agreement") for an all-stock transaction with North Immunology, Inc. ("North Immunology"), Nighthawk Merger Sub Corp., a wholly owned subsidiary of Aethlon, and Nighthawk Second Merger Sub, LLC, a wholly owned subsidiary of Aethlon. North Immunology is a privately held biotechnology company developing bispecific antibodies that target orthogonal inflammatory pathways in immune and inflammatory diseases ("I&I"), with the goal of delivering therapies that have the potential to offer best-in-disease efficacy, safety, and patient convenience.

 

The merger and concurrent private placement, which is expected to provide approximately $180 million in gross proceeds, are expected to position the combined company to advance the development of NOR-101, a potentially best-in-class half-life extended IL-13 x IL-18 bispecific antibody that is being developed for atopic dermatitis ("AD") and other immune-mediated diseases. Upon consummation of the transaction contemplated by the Agreement, the combined entity will operate as North Immunology, Inc. and trade on the Nasdaq Capital Market under a new ticker symbol NRTX.

 

Paid News Dissemination of behalf of AEMD

 

Read this news featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2026/09171-aethlon-aemd-merger-north-immunology.asp

 

The oversubscribed financing was supported by a syndicate of leading healthcare-focused institutional investors, including Bain Capital Life Sciences, Janus Henderson Investors, Deep Track Capital, Longitude Capital, Soleus Capital, Invus, Sirenia Capital Management LP, funds managed by Farallon Capital Management, Adage Capital Partners LP, and TCGX. The private placement is expected to provide North Immunology with approximately $180 million in gross proceeds (inclusive of the conversion of approximately $34 million of North Immunology's outstanding convertible promissory notes, together with any accrued interest, premiums and fees thereon, issued on or around the date hereof) and is expected to fully fund its operations into the second half of 2028.

 

"Monoclonal antibodies targeting type 2 inflammation have transformed the treatment of AD, yet the vast majority of patients still live with substantial disease burden" said Mohit Gupta, Co-Founder and CSO of North Immunology. "By simultaneously targeting type 2 and non-type 2 inflammatory pathways that drive AD, we believe NOR-101 has the potential to deliver a best-in-disease therapeutic profile."

 

North Immunology's Phase 1a study of NOR-101 is expected to begin in Q1 2027, with interim PK and safety data expected by mid-2027. North Immunology intends to rapidly initiate Phase 1b and Phase 2b studies for NOR-101 in atopic dermatitis in 2027 and deliver topline data for both studies in 2028.

 

"This merger and significant financing is expected to provide the capital and public-company platform needed to advance NOR-101 into clinical development," said Jonathan Barr, CEO of North Immunology. "We are encouraged by NOR-101's preclinical profile, including the promising bioavailability and approximately 42-day half-life observed in our non-human primate PK study. We look forward to executing on our clinical development plan, with multiple data readouts expected through 2028."

 

"We believe Aethlon stockholders will have a compelling opportunity to participate in the development of North Immunology's pipeline through their ownership interest in the combined company, while also retaining the potential to realize value from Aethlon's legacy assets through the contingent value rights," said James Frakes, Chief Executive Officer of Aethlon.

 

North Immunology was founded and incubated by ADAR1 Capital Management. "I am proud of the rapid progress our team has made in advancing NOR-101 since we founded the Company," said Daniel Schneeberger, co-founder and board member of North Immunology and managing partner of ADAR1 Capital. "We look forward to dosing our first clinical trial participant and building on this momentum as North enters its next stage of growth."

 

About the Proposed Transaction

Under the terms of the merger agreement, as of the closing of the proposed merger, the pre-merger Aethlon stockholders are expected to own approximately 4.75% of the combined company, and the pre-merger North Immunology stockholders (inclusive of those investors participating in the Private Placement) are expected to own approximately 95.25% of the combined company, which is expected to have a pro forma equity value of approximately $346.5 million (inclusive of the Private Placement). The percentage of the combined company that Aethlon's stockholders will own as of the closing of the proposed merger is subject to reduction to the extent Aethlon's net cash at closing is less than $0, as further described in the Agreement.

 

In addition, Aethlon stockholders as of immediately prior to the closing (the "Holders") will be entitled to receive additional financial consideration through a contingent value right (a "CVR") for each share of Aethlon common stock and preferred stock held, entitling the Holders to net proceeds (if any) received following the closing from a sale, license, transfer, divestiture or other monetization transaction with respect to Aethlon's legacy Hemopurifier® business (a "Parent Legacy Transaction"), the terms of which will be described in the Agreement and/or the Form 8-K to be filed in connection with the proposed transaction.

 

The transaction has received approval by the Board of Directors of both companies and is expected to close in the first quarter of 2027, subject to certain closing conditions, including, among others, approval by the stockholders of each company, the effectiveness of a registration statement to be filed with the U.S. Securities and Exchange Commission (the "SEC") to register the securities to be issued in connection with the proposed merger, Nasdaq's approval of the initial listing application to be submitted in connection with the proposed merger, and the satisfaction of other customary closing conditions.

 

The combined company plans to operate under the name North Immunology, Inc. and will be led by North Immunology's existing management team. North Immunology's existing Board of Directors, chaired by Daniel Schneeberger, M.D., MBA, co-founder of North Immunology and managing partner of ADAR1 Capital Management, will become directors of the combined company, alongside a number of new independent directors.

 

Maxim Group LLC is serving as financial advisor and Procopio, Cory, Hargreaves & Savitch LLP is serving as legal counsel to Aethlon. Wedbush Securities Inc. is serving as exclusive strategic financial advisor and Gibson, Dunn & Crutcher LLP is serving as legal counsel to North Immunology. Jefferies, Leerink Partners, BofA Securities and UBS Investment Bank are serving as the placement agents to North Immunology. Cooley LLP is serving as legal counsel to the placement agents.

 

About Aethlon Medical

Aethlon Medical, Inc. (Nasdaq: AEMD) is a medical therapeutic company focused on developing the Hemopurifier®, a clinical-stage immunotherapeutic device designed for the depletion of cancer-promoting exosomes and life-threatening viruses from the circulatory system, and for use in organ transplantation. Aethlon is headquartered in San Diego, California.

 

About North Immunology

North Immunology is a privately held biotechnology company developing bispecific antibodies that target orthogonal inflammatory pathways in immune and inflammatory diseases ("I&I") with the goal of delivering therapies that have the potential to offer best-in-disease efficacy, safety, and patient convenience. North Immunology's lead program, NOR-101, is a half-life extended anti-IL-13 x IL-18 bispecific antibody designed to inhibit both the type 2 and non-type 2 inflammation that drives atopic dermatitis. For more information, visit: www.northimmunology.com.

 

Forward-Looking Statements

Certain statements in this press release, other than purely historical information, may constitute "forward-looking statements" within the meaning of the federal securities laws, including for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, express or implied statements relating to Aethlon's and North Immunology's expectations, hopes, beliefs, intentions or strategies regarding the proposed merger, the Private Placement, and the combined company's future, pipeline and business including, without limitation, statements regarding the expected timing and completion of the proposed merger and the Private Placement, the anticipated ownership structure of the combined company, the expected benefits, opportunities and market potential of the proposed transaction, the combined company's expected cash position and cash runway, the target profile, anticipated benefits, mechanism, dosing and development plans for NOR-101 and North Immunology's other product candidates, the timing and design of preclinical studies and clinical trials and the expected timing of data, market size and opportunity, and the combined company's ability to achieve the expected benefits or opportunities with respect to its product candidates, including whether NOR-101 will achieve clinical proof of concept, demonstrate improved efficacy relative to type 2-directed therapies, achieve extended maintenance dosing intervals, reduce the incidence of conjunctivitis, or achieve regulatory approval, and statements made herein with respect to the contingent value rights entitling the Holders to proceeds (if any) from a Parent Legacy Transaction received post-closing. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting the combined company will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Aethlon's, North Immunology's or the combined company's control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to, risks related to: the risk that the proposed merger and the Private Placement may not be completed on the anticipated timeline or at all; the failure to satisfy the conditions to closing, including obtaining the requisite approvals of the stockholders of each company, the effectiveness of the registration statement to be filed with the SEC in connection with the proposed merger, approval of the Nasdaq initial listing application, and the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended; the risk that the Private Placement may not close or may not result in the anticipated gross proceeds; the amount of Aethlon's net cash at closing and the resulting adjustment to the exchange ratio; the risk that a Parent Legacy Transaction may not be completed and that no payment may become due in respect of the CVRs; the outcome of preclinical studies and clinical trials; regulatory processes and the possibility that the target profile for NOR-101 is not achieved; the fact that NOR-101 is investigational and that comparisons to other agents are not based on head-to-head studies; the combined company's ability to successfully develop and commercialize its product candidates; competition in the atopic dermatitis market; the combined company's reliance on third parties; protection of intellectual property, including the combined company's ability to obtain and maintain rights to the intellectual property underlying NOR-101; and the combined company's need for substantial additional funding. Should one or more of these risks or uncertainties materialize, or should any of Aethlon's, North Immunology's or the combined company's assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Nothing in this press release should be regarded as a representation by any person that the forward-looking statements set forth therein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein and in Aethlon's filings with the SEC. Aethlon, North Immunology and the combined company do not undertake or accept any duty to make any updates or revisions to any forward-looking statements, except as required by law.

 

Important Information About Investigational Product Candidates

This press release concerns drug candidates that are under preclinical and clinical investigation, and which have not yet been approved by the U.S. Food and Drug Administration. These are currently limited by federal law to investigational use, and no representation is made as to their safety or effectiveness for the purposes for which they are being investigated. No clinical studies of NOR-101 have been conducted, and results from clinical trials of other agents are not indicative of results that may be demonstrated in clinical studies of NOR-101. Comparisons to approved products and to other investigational product candidates are based on separate studies with different designs, endpoints, timepoints and patient populations; no head-to-head studies have been conducted, and such comparisons are for illustrative purposes only.

 

No Offer or Solicitation

This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy any securities, or a solicitation of any proxy, vote, consent or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. The securities to be sold in the Private Placement are being offered in a transaction not involving a public offering and have not been registered under the Securities Act of 1933, as amended, or any state securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements.

 

NEITHER THE SEC NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THE SECURITIES OR DETERMINED IF THIS COMMUNICATION IS TRUTHFUL OR COMPLETE.

 

Important Additional Information About the Proposed Transaction Will Be Filed with the SEC

In connection with the proposed merger, Aethlon intends to file relevant materials with the SEC, including a registration statement on Form S-4 that will contain a proxy statement/prospectus relating to the proposed transaction. This press release is not a substitute for the registration statement, proxy statement/prospectus or any other document that Aethlon may file with the SEC in connection with the proposed transaction.

 

INVESTORS AND SECURITY HOLDERS OF AETHLON AND NORTH IMMUNOLOGY ARE URGED TO READ THE REGISTRATION STATEMENT, PROXY STATEMENT/PROSPECTUS AND ANY OTHER RELEVANT DOCUMENTS FILED OR TO BE FILED WITH THE SEC, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS THERETO, CAREFULLY AND IN THEIR ENTIRETY IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT AETHLON, NORTH IMMUNOLOGY, THE PROPOSED TRANSACTION AND RELATED MATTERS.

 

Investors and security holders will be able to obtain free copies of the registration statement, proxy statement/prospectus and other documents filed by Aethlon with the SEC through the website maintained by the SEC at www.sec.gov and on the Investors section of Aethlon's website.

 

Participants in the Solicitation

Aethlon, North Immunology and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Aethlon's stockholders in connection with the proposed transaction. Information about Aethlon's directors and executive officers, including a description of their interests in Aethlon, is included in Aethlon's most recent definitive proxy statement, as filed with the SEC on September 1, 2026, and in Aethlon's Annual Report on Form 10-K for the fiscal year ended March 31, 2026. To the extent that holdings of Aethlon securities by Aethlon's directors and executive officers have changed since the amounts set forth in Aethlon's most recent definitive proxy statement, such changes have been or will be reflected on Statements of Change in Ownership on Forms 3, 4 or 5 filed with the SEC. Additional information regarding the persons who may, under the rules of the SEC, be deemed participants in the solicitation of proxies in connection with the proposed transaction, including a description of their direct or indirect interests, by security holdings or otherwise, will be included in the registration statement and proxy statement/prospectus when filed with the SEC.

 

Investor Contact

Susan Noonan

S.A. Noonan Communications, LLC

susan@sanoonan.com

 

 

Full news

https://www.aethlonmedical.com/news-media/press-releases/detail/529/aethlon-medical-north-immunology-announce-merger-to

 

Aethlon Medical, Inc. (Nasdaq: AEMD)  is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Aethlon Medical, Inc. is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

 

Research biotech and medical device/ tech stocks at Investorideas.com

https://www.investorideas.com/BIS/

 

 

 

 

 

About Investorideas.com – Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Investor Ideas digital advertising and guest posts service :

https://www.investorideas.com/Advertise/

 

Follow us on X @investorideas @stocknewsbites

Follow us on Facebook https://www.facebook.com/Investorideas

Follow Investorideas and the Exploring Mining Podcast on YouTube https://www.youtube.com/c/Investorideas

 

Investors stay ahead by signing up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

Join our free Telegram community

https://t.me/+o8DxSAgeNCk2ZGVh

 

Contact us for more info  

Call 800 665 0411

 

This article was originally posted on Investorideas.com https://www.investorideas.com/CO/AEMD/news/2026/09171-aethlon-aemd-merger-north-immunology.asp

 

 

 

 

AI Defense Stock VisionWave ( Nasdaq: $VWAV) Files U.S. Patent Application for ARGUS, a Proposed Space-Enabled AI Counter-Drone Architecture; @VWAVInc

 

AI Defense Stock VisionWave ( Nasdaq: $VWAV) Files U.S. Patent Application for ARGUS, a Proposed Space-Enabled AI Counter-Drone Architecture; @VWAVInc

 

 

 

 

Investorideas.com, a top rated investment site for retail Investors following AI and defense stocks, reports on breaking news and trading for VisionWave Holdings, Inc (Nasdaq:VWAV), an advanced defense technology company specializing in artificial intelligence, autonomous systems, RF sensing, and next-generation defense technologies.

 

VisionWave Holdings, Inc today announced that it has filed a U.S. non-provisional patent application with the U.S. Patent and Trademark Office (the “USPTO”) describing ARGUS™, a proposed space-enabled, AI-driven counter-unmanned aircraft system (C-UAS) architecture that the Company is developing.

 

Paid News Dissemination on behalf of VWAV 

 

Read this news, featuring VWAV in full at https://www.investorideas.com/CO/VWAV/news/2026/09141-visionwave-vwav-argus-patent-counter-drone-architecture.asp

 

The U.S. patent application, Serial No. 19/797,497, filed on September 4, 2026, 2026, is titled “Systems and Methods of Detecting and Countering Drone Attacks by Space-Enabled, AI-Driven Counter-UAS Architecture.” The application claims priority to U.S. provisional patent application Serial No. 63/940,940, filed on December 15, 2025, and describes an integrated architecture intended to detect, classify, track, evaluate, and respond to hostile drones and other low-altitude aerial threats over wide geographic areas. The application has not yet been examined by the USPTO. Patent applications are frequently rejected or allowed only with claims narrower than those originally filed, and there can be no assurance that any patent will issue from the application, that the scope of any issued claims will be the same as the claims as filed, or that any patent that issues will provide VisionWave with a competitive advantage or withstand challenge.

 

As described in the application, ARGUS is intended to combine space-based surveillance, artificial intelligence, ground-based sensing, resilient communications, cybersecurity, command and control, and multiple types of defensive effectors into a coordinated counter-UAS system.

 

ARGUS is an architecture described in a pending patent application and remains in development. ARGUS has not been built, integrated or tested as a system, and no prototype of the complete architecture exists. VisionWave does not own or operate any satellites and has no agreement with any satellite operator, launch provider, government agency or other party for the space segment or any other element of ARGUS. The capabilities described in this press release are those set out in the application; they have not been demonstrated or independently validated. Developing, testing and fielding ARGUS would require substantial additional capital, third-party participation and government authorizations, none of which is assured, and ARGUS has not generated any revenue.

 

The patent application describes a space segment incorporating satellites equipped with electro-optical and infrared sensors, with optional synthetic aperture radar and RF sensing capabilities, intended to provide wide-area surveillance and early detection. Under the described architecture, information collected from space would be combined with information from ground-based radar, RF, and EO/IR sensors to form a unified recognized air picture.

 

A central element of the described architecture is an AI-based object-recognition methodology designed to analyze the structural geometry of airborne objects. Rather than relying solely on conventional image classification, the methodology described in the application is designed to identify structural key points such as rotor hubs, arms, fuselage features, wings, and payload attachment points and to use multi-view information to generate virtual three-dimensional representations of potential targets. This approach is intended to improve classification where a target is partially obscured or observed from difficult viewing angles; its performance has not been validated through testing

 

The application also describes multi-sensor fusion and AI-based threat assessment, combining information from satellites, radar, RF detectors, EO/IR sensors, and other sources. The described system is designed to update target tracks and threat scores continuously as additional evidence becomes available and to use those assessments within command-and-control logic to determine whether an object should be monitored, generate a warning, or be considered for engagement, with any engagement subject to authorization by a human operator.

Another component of the disclosed architecture is SkyWeave™, an AI-controlled high-frequency (HF) communications backbone, also in development, designed to provide resilient beyond-line-of-sight command and control. As described in the application, the HF network would dynamically evaluate ionospheric conditions, interference, link quality, mission requirements, and other factors to select frequencies, transmission power, antenna configurations, relay nodes, and communications routes. The architecture is intended to maintain command connectivity when SATCOM, cellular, microwave, or terrestrial communications are degraded, jammed, or unavailable.

 

The application also describes a security architecture for protecting command, communications, and navigation information, including authentication, encryption, session security, key establishment, and synchronous or asynchronous key-exchange techniques designed for constrained and intermittently available communications environments.

 

The described system is designed to coordinate a layered mix of defensive responses rather than depend upon a single interceptor technology. Depending upon mission conditions, threat assessment, communications availability, rules of engagement, and collateral-risk considerations, the architecture described in the application would coordinate interceptor drones, RF jammers, deceptive navigation techniques, kinetic systems, directed-energy systems, high-power microwave systems, and other effectors. In the United States, the use of RF jamming, navigation spoofing and certain other counter-UAS mitigation technologies is restricted by federal law and is generally limited to specifically authorized government agencies, and similar restrictions apply in many other jurisdictions. These restrictions may limit the potential customers for, and permitted uses of, ARGUS.

 

“ARGUS represents our vision for moving counter-drone defense toward an intelligent, distributed defense architecture,” said Danny Rittman, Chief Technology Officer of VisionWave.

 

“The objective is to connect detection, artificial intelligence, resilient communications, cybersecurity, command and control, and multiple defensive technologies into a single coordinated system. By combining space-based awareness with terrestrial sensors and resilient HF communications, ARGUS is being designed for the increasingly contested environments in which we believe future counter-UAS systems will need to operate.”

 

The patent application additionally describes predictive trajectory modeling and defensive swarm concepts. Under the described approach, AI models would forecast likely target positions and behavior, allowing defensive assets to be positioned along predicted ingress corridors, and the architecture would coordinate defensive drones using global sensor information, resilient HF communications, encrypted navigation information, and local autonomous control.

 

VisionWave believes the filing is a step in the development of ARGUS and is consistent with the Company’s broader strategy of developing AI-enabled, resilient, and distributed defense technologies intended to operate across space, RF, cyber, autonomous, and physical domains.

 

About ARGUS™

ARGUS™ is a proposed space-enabled counter-UAS architecture, in development by VisionWave and described in a pending U.S. patent application, that is designed to integrate wide-area sensing, artificial intelligence, multi-sensor fusion, resilient communications, secure command and control, and layered countermeasure technologies. The architecture is intended to support defense against small unmanned aircraft, autonomous aerial systems, loitering munitions, and coordinated drone threats across geographically distributed operating environments. ARGUS has not been commercialized, is not available for sale and has not generated any revenue.

 

About VisionWave Holdings, Inc.

VisionWave Holdings, Inc. (Nasdaq: VWAV) is a defense and advanced sensing technology company developing AI-driven, RF-based sensing, autonomy, and computational acceleration technologies for defense, homeland security, and commercial infrastructure applications. VisionWave's mission is to connect defense innovation with civilian progress through shared core technologies deployed across air, land, and fixed-site environments. The Company's website is https://www.vwav.inc. Information contained on, or accessible through, the Company’s website is not incorporated by reference into, and does not form a part of, this press release or any filing of the Company with the Securities and Exchange Commission.

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and such statements are intended to be covered by the safe harbor provisions of those laws. All statements other than statements of historical fact are forward-looking statements, including statements regarding the prosecution of U.S. Patent Application Serial No. 19/797,497 and the scope of any patent that may issue from it; the design, development, capabilities, testing, performance, potential applications, commercialization and future deployment of ARGUS, SkyWeave and other VisionWave technologies; the Company’s ability to obtain the satellite, communications, effector and other capabilities, third-party participation and government authorizations that the ARGUS architecture contemplates; and the Company’s business strategy. Forward-looking statements are generally identified by words such as “anticipate,” “believe,” “continue,” “could,” “designed to,” “estimate,” “expect,” “intend,” “intended to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “vision,” “will,” “would” and similar expressions, although not all forward-looking statements contain these identifying words.

 

Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those expressed or implied, including, among others: the risk that the USPTO rejects the application or allows only claims narrower than those sought, that any patent that issues is challenged, invalidated or circumvented, or that third parties hold patents that the ARGUS architecture would infringe; the early stage of development of ARGUS and SkyWeave, which have not been built or tested as integrated systems and may never be successfully developed; the Company’s need for substantial additional capital to develop ARGUS and its other technologies, which may not be available on acceptable terms or at all, and the dilution that may result from equity financings, including sales under the Company’s at-the-market offering programs, conversions of outstanding convertible debentures and exercises of outstanding warrants; the Company’s dependence on third parties for satellites, launch services, space-based data, effectors and other elements that it does not own or produce; legal restrictions on the use of RF jamming, navigation spoofing, directed-energy and other counter-UAS mitigation technologies, and the need for spectrum, export and other governmental authorizations; U.S. export control laws and regulations, including the International Traffic in Arms Regulations and the Export Administration Regulations, and any secrecy order that may be imposed with respect to the application; the lengthy, uncertain and budget-dependent nature of government procurement, and the absence of any contract or award for ARGUS; competition from larger, better-capitalized defense contractors; the performance and reliability of artificial-intelligence models; cybersecurity risks; the Company’s limited operating history and revenue, history of losses and the substantial doubt about its ability to continue as a going concern; the Company’s ability to maintain compliance with The Nasdaq Stock Market’s continued listing requirements, including the minimum bid price requirement; and the other risks described under “Risk Factors” in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2025, its subsequent Quarterly Reports on Form 10-Q and its other filings with the Securities and Exchange Commission, available at www.sec.gov.

 

Forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by these cautionary statements. Readers should not place undue reliance on forward-looking statements. VisionWave undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.

Contact for Investors: investors@vwav.inc

VisionWave Holdings is a Featured Defense stock on Investorideaas.om

https://www.investorideas.com/CO/VWAV/

Research more defense stocks at Investorideas stock directory

https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp

Disclaimer/Disclosure: VisionWave Holdings, Inc. is a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions. More disclaimer info:  Learn more about publishing your news release and our other news services on the Investorideas.com newswire. Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:  https://www.investorideas.com/About/Private_Policy.asp

About Investorideas.com - Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas

https://www.investorideas.com/Advertise/

 

Follow & Contact

Follow us on X: @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube @Investorideas

 

This article was originally posted on Investorideas.com

https://www.investorideas.com/CO/VWAV/news/2026/09141-visionwave-vwav-argus-patent-counter-drone-architecture.asp